#ACR22 Abstr#0826 2 years on since FDA approved #Tocilizumab in Adults Onset Still’s Disease, real-world data from Japan affirmed its effectiveness and as a steroid-sparring agent @RheumNow https://t.co/jbmhEnGwXO